Focus on Patients

  1. Building Patient Trust In Research Through Connection Driven-Transparency 2/4/2026

    The question is not whether trust matters but how industry, sponsors, and investigators can bridge the trust gap to drive patient participation.

  2. Patient Trust In Pharma Is Low; Here's How To Rebuild It 2/2/2026

    CISCRP's Annick de Bruin and Shalome Sine provide strategies for building patient trust based on the findings from their Perceptions & Insights Study.

  3. How Gilead Includes Patients Most Affected By HIV In Its PrEP Trials 1/26/2026

    VP of Clinical Development, HIV, Moupali Das shares how the sponsor approaches diverse participant recruitment and enrollment, highlighting the importance of early demographic research and careful, intentional PI selection.

  4. Confronting "Time Toxicity" In Global Oncology And Rare Disease Trials For Operational Excellence And Patient Retention 1/14/2026

    Time is the only truly finite resource in a clinical trial. Consultant Leila Cupersmith discusses how sponsors can better design trials with a lower time burden to boost enrollment, retention, and overall operational excellence.

  5. Working (Well) With Patient Advocates: The Sponsor POV 1/12/2026

    Aeovian CEO Allison Hulme reflects on Aeovian Pharmaceuticals' partnership with the TSC Alliance and how it’s informed research and development of their first-in-class selective mTORC1 inhibitor. 

  6. Working (Successfully) With Pharma: A PAG's Perspective 1/12/2026

    TSC Alliance President and CEO Kari Rosbeck details the patient advocacy group's unique and fruitful relationship with Aeovian Pharmaceuticals in developing the company's first-in-class selective mTORC1 inhibitor for TSC-related refractory epilepsy.

  7. Making Medical Innovation Matter To Patients With Simplified Trial Design 1/9/2026

    To be a leader in today’s environment, Lexicon Pharmaceuticals CMO Craig Granowitz, MD, Ph.D., says companies must embrace simplified clinical trial designs, which can reduce regulatory risks, lower R&D costs, and shorten clinical timelines.

  8. Researchers Want A Design Shake-Up In 2026 1/7/2026

    When asked what clinical research professionals should leave behind in 2025, quite a few lamented the stale, even problematic, approach to clinical trial design. Here's what they want done differently in 2026.

  9. FDA Further Expands And Clarifies Expanded Access FAQs 12/29/2025

    Healthcare attorney Dianne J. Bourque breaks down the FDA's October 2025 update to its Expanded Access FAQs.

  10. Most Ex-U.S. Countries Can't Access The Medicines They Help Study 12/19/2025

    When a country hosts a clinical trial, we assume patients there will eventually benefit from the therapy they helped test. Research Jennifer E. Miller, Ph.D., says that's not often the case.